Pharmacokinetics and Tolerability of Meloxicam Injected Intramuscularly vs. Tablet in Healthy Subjects

Inclusion Criteria: * Healthy subjects as determined by results of screening * Written informed consent in accordance with Good Clinical Practice and local legislation * Age ≥ 18 and ≤ 50 years * Broca \> - 20% and \< + 20% Exclusion Criteria: * Any findings of the medical examination (including laboratory, blood pressure, pulse rate and electrocardiogram (ECG)) deviating from normal and of clinical relevance * Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders * Surgery of the gastro-intestinal tract ( except appendectomy) * Diseases of the central nervous system (such as epilepsy) or psychiatric disorders * Chronic or relevant acute infections * Hypersensitivity to meloxicam and/or non-steroidal antirheumatic agents * Intake of drugs with a long half-life (\>24 hours) (≤ 1 month prior to administration or during the trial) * Use of any drugs which might influence the results of the trial (≤ 10 days prior to administration or during the trial) * Participation in another trial with an investigational drug (≤ 2 months prior to administration or during the trial) * Smoker (\>= 10 cigarettes or \>= 3 cigars or \>= 3 pipes/day) * Inability to refrain from smoking on study days * Known alcohol abuse * Known drug abuse * Blood donation (≤ 1 month prior to administration) * Excessive physical activities (≤ 5 days prior to administration) * History of hemorrhagic diatheses * History of gastro-intestinal ulcer, perforation or bleeding * History of bronchial asthma * For female subjects: * Pregnancy * Positive pregnancy test * No adequate contraception e.g. sterilization, IUD (intrauterine device), oral contraceptives * Inability to maintain this adequate contraception during the whole study period * Lactation period